Fingerprint
Dive into the research topics of 'MAPK activation predicts poor outcome and the MEK inhibitor, selumetinib, reverses antiestrogen resistance in ER-positive high-grade serous ovarian cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically